Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097706 | 0.77 | MAPT (0.30) | MAPTKDM4EALOX15SMN1; SMN2 | |
| SCHEMBL19953391 | 0.77 | MAPT (0.36) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL2051249 | 0.75 | MAPT (0.44) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| SCHEMBL25212735 | 0.73 | — | — | |
| SCHEMBL7168637 | 0.73 | MAPT (0.38) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| SCHEMBL21618434 | 0.73 | MAPT (0.33) | MAPTKDM4ESMN1; SMN2CYP1A2CYP2C9 | |
| Trolamine SCHEMBL15845959 | 0.71 | MAPT (0.47) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL1146 | 0.71 | MAPT (0.47) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL434089 | 0.71 | MAPT (0.47) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL4748243 | 0.71 | MAPT (0.47) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104945770-A | Thermal-aging-resistant modified polyvinyl chloride woven bag | WUHU YOUXIN LASER MOULD CO LTD | 2015-09-30 | — | — | CN | disclosed |
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CEVC GREGOR (DE) | 2014-01-16 | — | — | US | disclosed |
| EP-0901623-B1 | PROCESS FOR SEPARATING MIXTURES OF SUBSTANCES USING CAPILLARY AFFINITY GEL ELECTROPHORESIS | ZEPTOSENS AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-6379515-B1 | SEPARATING AN ELECTRIC CHARGED TARGET MOLECULES WITH ELECTROPHORESIS | NOVARTIS AG (CH) | 2002-04-30 | — | — | US | disclosed |
| EP-0901623-A1 | PROCESS FOR SEPARATING MIXTURES OF SUBSTANCES USING CAPILLARY AFFINITY GEL ELECTROPHORESIS | Novartis AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997045721-A1 | PROCESS FOR SEPARATING MIXTURES OF SUBSTANCES USING CAPILLARY AFFINITY GEL ELECTROPHORESIS | NOVARTIS AG (CH) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CD68, CHMP4B, ANXA5 | MAPT 82/4885KDM4E 3918/4885ALOX15 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.